Concurrent inhibition of EGFR (by gefitinib) and HGF/c-MET (via crizotinib or SU11274) significantly affected HNSCC cell line proliferation, invasion, and wound healing compared to individual inhibitors. Here, MET is linked to head and neck squamous cell carcinoma.